A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs KD 025 (Primary)
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- Sponsors Kadmon Corporation
- 09 Jul 2019 According to a Kadmon Holdings media release, the first patient has been dosed for this study.
- 17 Apr 2019 Status changed from planning to recruiting.
- 14 Mar 2018 New trial record